Menu
Search
|

Menu

Close
X

Foundation Medicine Inc FMI.OQ (NASDAQ Stock Exchange Global Select Market)

136.70 USD
+0.30 (+0.22%)
As of 4:00 PM EDT
chart
Previous Close 136.40
Open 136.45
Volume 260,892
3m Avg Volume 133,209
Today’s High 136.70
Today’s Low 136.40
52 Week High 137.10
52 Week Low 31.70
Shares Outstanding (mil) 37.04
Market Capitalization (mil) 5,053.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
53
FY17
153
FY16
117
FY15
93
EPS (USD)
FY18
-1.017
FY17
-4.506
FY16
-3.249
FY15
-2.721
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.54
Price to Sales (TTM)
vs sector
28.17
8.28
Price to Book (MRQ)
vs sector
266.60
4.21
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
476.29
17.68
LT Debt to Equity (MRQ)
vs sector
476.29
13.20
Return on Investment (TTM)
vs sector
-120.21
13.09
Return on Equity (TTM)
vs sector
-209.94
15.10

EXECUTIVE LEADERSHIP

Michael Pellini
Chairman of the Board, Since 2017
Salary: $511,808.00
Bonus: --
Troy Cox
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Jason Ryan
Chief Financial Officer, Principal Financial Officer, Principal Accounting officer, Since 2015
Salary: --
Bonus: --
Konstantin Fiedler
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Robert Hesslein
Senior Vice President, General Counsel, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

150 2nd St
CAMBRIDGE   MA   02141-2115

Phone: +1617.4182200

Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer. Its suite of clinical molecular information products includes FoundationOne, which is used for solid tumors; FoundationOne Heme, which is used for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma, pediatric cancers and advanced sarcoma; FoundationACT (Assay for Circulating Tumor DNA), which is a blood-based (liquid biopsy) assay that evaluates circulating tumor deoxyribonucleic acid (ctDNA), and FoundationFocus CDxBRCA, which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with Rubraca (rucaparib).

SPONSORED STORIES